Persistence of CD16+/CD56-/2B4+ natural killer cells: A highly dysfunctional NK subset expanded in ocular myasthenia gravis

Journal of Neuroimmunology

Volumn 179, Issue 1-2, 2006, Pages 117-125

  Nguyen, Stéphanie ^a   Morel, Véronique ^a   Le Garff Tavernier, Magali ^a   Bolgert, Francis ^a   Leblond, Véronique ^a   Debré, Patrice ^a   Vieillard, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

2B4; Lymphoproliferative disorder; Myasthenia gravis; NK cells

Indexed keywords

AZATHIOPRINE; CD48 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 18 BINDING PROTEIN; METHOTREXATE; PREDNISONE; PYRIDOSTIGMINE; TRANSFORMING GROWTH FACTOR BETA;

AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CD16+ CD56+ 2B4+ NATURAL KILLER CELL; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DONOR; DRUG SUBSTITUTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; MALE; MYASTHENIA GRAVIS; NATURAL KILLER CELL; OCULAR MYASTHENIA GRAVIS; PRIORITY JOURNAL; REMISSION; TARGET CELL; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, CD56; AZATHIOPRINE; CHOLINESTERASE INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERFERON-GAMMA; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MEMBRANE GLYCOPROTEINS; MYASTHENIA GRAVIS; PHENOTYPE; PYRIDOSTIGMINE BROMIDE; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748981849     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.05.028     Document Type: Article

References (37)

1. Antonioli C.M., and Airo P. Dermatomyositis associated with lymphoproliferative disorder of NK cells and occult small cell lung carcinoma. Clin. Rheumatol. 23 (2004) 239-241
2. Assarsson E., Kambayashi T., Schatzle J.D., Cramer S.O., von Bonin A., Jensen P.E., Ljunggren H.G., and Chambers B.J. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J. Immunol. 173 (2004) 174-180
3. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debré P., and Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277 (1997) 112-116
4. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., and Caligiuri M.A. NK cell and DC interactions. Trends Immunol. 25 (2004) 47-52
5. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
6. Ferlazzo, G., Tsang, M.L., Moretta, L., Melioni, G., Steinman, R.M., Munz, C., 2002. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.
7. Fukushima K., Ikehara Y., and Yamashita K. Functional role played by the glycosylphosphatidylinositol anchor glycan of CD48 in interleukin-18-induced interferon-gamma production. J. Biol. Chem. 280 (2005) 18056-18062
8. Harada M., Lin T., Kurosawa S., Maeda T., Umesue M., Itoh O., Matsuzaki G., and Nomoto K. Natural killer cells inhibit the development of autoantibody production in (C57BL/6 × DBA/2) F1 hybrid mice injected with DBA/2 spleen cells. Cell. Immunol. 161 (1995) 42-49
9. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., and Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15 (2001) 2140-2148
10. Jander S., and Stoll G. Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 59 (2002) 287-289
11. Johansson S., Berg L., Hall H., and Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol. 26 (2005) 613-618
12. Kubin M.Z., Parshley D.L., Din W., Waugh J.Y., Davis-Smith T., Smith C.A., Macduff B.M., Armitage R.J., Chin W., Cassiano L., Borges L., Petersen M., Trinchieri G., and Goodwin R.G. Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur. J. Immunol. 29 (1999) 3466-3477
13. Lima M., Almeida J., Montero A.G., Teixeira Mdos A., Queiros M.L., Santos A.H., Balanzategui A., Estevinho A., Alguero Mdel C., Barcena P., Fonseca S., Amorim M.L., Cabeda J.M., Pinho L., Gonzalez M., San Miguel J., Justica B., and Orfao A. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+ dim chronic natural killer cell large granular lymphocytosis. Am. J. Pathol. 165 (2004) 1117-1127
14. Maity R., Nair S.R., Caspi R.R., and Nelson L.M. Post-thymectomy murine experimental autoimmune oophoritis is associated with reduced natural killer cell activity. Am. J. Reprod. Immunol. 38 (1997) 360-365
15. Mavilio D., Lombardo G., Benjamin J., Kim D., Follman D., Marcenaro E., O'Shea M.A., Kinter A., Kovacs C., Moretta A., and Fauci A.S. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2886-2891
16. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., Biassoni R., and Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19 (2001) 197-223
17. Nguyen S., Dhedin N., Vernant J.P., Kuentz M., Al Jijakli A., Rouas-Freiss N., Carosella E.D., Boudifa A., Debre P., and Vieillard V. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105 (2005) 4135-4142
18. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., and Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 (1995) 88-91
19. Osserman K.E., and Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt. Sinai J. Med. 38 (1971) 497-537
20. Parolini S., Bottino C., Falco M., Augugliaro R., Giliani S., Franceschini R., Ochs H.D., Wolf H., Bonnefoy J.Y., Biassoni R., Moretta L., Notarangelo L.D., and Moretta A. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192 (2000) 337-346
21. Pazmany L. Do NK cells regulate human autoimmunity?. Cytokine 32 (2005) 76-80
22. Pridgeon C., Lennon G.P., Pazmany L., Thompson R.N., Christmas S.E., and Moots R.J. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56 bright, CD94 bright, CD158 negative phenotype. Rheumatology 42 (2003) 870-878
23. Raulet D.H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat. Immunol. 5 (2004) 996-1002
24. Rose M., and Berliner N. T-cell large granular lymphocyte leukemia and related disorders. The Oncologist 9 (2004) 247-258
25. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., Van Kaer L., and Ljunggren H.G. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1 (2000) 245-251
26. Sivori S., Parolini S., Falco M., Marcenaro E., Biassoni R., Bottino C., Moretta L., and Moretta A. 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30 (2000) 787-793
27. Takahashi K., Aranami T., Endoh M., Miyake S., and Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 127 (2004) 1917-1927
28. Takeda K., and Dennert G. The development of autoimmunity in C57/BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J. Exp. Med. 177 (1993) 155-164
29. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
30. Valiante N.M., and Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178 (1993) 1397-1406
31. Vieillard V., Strominger J.L., and Debre P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10981-10986
32. Vincent A., Palace J., and Hilton-Jones D. Myasthenia gravis. Lancet 357 (2001) 2122-2128
33. Vivier E., and Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat. Immunol. 6 (2005) 17-21
34. Walzer T., Dalod M., Zitvogel L., and Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 106 (2005) 2252-2258
35. Yabuhara A., Yang F.C., Nakazawa T., Iwasaki Y., Mori T., Koike K., Kawai H., and Komiyama A. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J. Rheumatol. 23 (1996) 171-177
36. Yuan D., Roh C.Y., and Wilder J.A. Interactions between B lymphocytes and NK cells. FASEB J. 8 (1994) 1012-1018
37. Zhang B., Yamamura T., Kondo T., Fujiwara M., and Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186 (1997) 1677-1687